Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Clinical Trials in Japan / NCT03729232
Recruiting Observational

Japanese Catheter Ablation Registry

NCT03729232 · tracked via the Priya Life Science Japan tracker
Sponsor
National Cerebral and Cardiovascular Center, Japan
Phase
Observational
Started
2017-07-01
Last updated
2023-11-13

Condition(s) studied

Catheter AblationCardiac Arrhythmias

Study summary

Japanese Cather Ablation (J-AB) Registry is a voluntary nationwide registry, performed by Japanese Heart Rhythm Society, collaborated with the National Cerebral and Cardiovascular Center. The objectives of this registry are to observe and describe developments in the catheter ablation treatment of arrhythmia in Japan and to provide reliable information on the type of activity performed and the facilities available in Japanese arrhythmia units.

Eligibility

Sex
ALL
Min age
—
Max age
—
Healthy volunteers
No
Inclusion Criteria: * Patients treated with catheter ablation in Japan Exclusion Criteria: * Patients who refused to consent

Primary outcome measure(s)

  • Number of patients with recurrence of targeted arrhythmia — Through discharge from hospital, approximately up to 1 weeks

Trial sites (1)

FacilityCityRegionStatus
National Cerebral and Cardiovascular Center Suita Osaka Recruiting

More National Cerebral and Cardiovascular Center, Japan trials in Japan

REASSURE-NIRS Registry Recruiting
Japanese Lead Extraction Registry Recruiting
National Cerebral and Cardiovascular Center (NCVC) Stroke Registry Active, not recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT03729232 on ClinicalTrials.gov ↗ ← All trials in Japan